The non-exclusive deal is with miDiagnostics, a spin-off of Belgian research lab imec set up with Johns Hopkins University in the US which specializes in the development of point-of-care tests for screening, diagnosing and monitoring a wide range of health conditions.
The patented technology takes aerosols and droplets from exhaled breath for screening for viral RNA through miDiagnostics’ ultrafast PCR technology. The agreement enables miDiagnostics to kickstart the commercialization of a Covid-19 breathalyzer, rather than using samples from blood, saliva or the nose and throat.
- Five-minute breath test for Covid-19
- imec creates 50nm finFET biological sensor
- A CMOS-compatible biosensor chip for infectious disease
In the past year, imec developed a breath sampler and performed clinical studies with the university hospital and university of Leuven showing that imec’s breath sampler is capable of capturing the SARS-CoV-2 virus in exhaled air, and detecting the viral RNA quickly and reliably.
imec also developed a sampling instrument integrating the breath sampling technology and imec’s ultra-fast PCR-test, and optimized the robustness and ease of use, to achieve a functioning proof-of-concept to date.
“I note with great pride that we have run an impressive course in the past months,”
“We have succeeded in transforming a promising concept and groundbreaking technology into a functional proof-of-concept that has passed both user tests and clinical studies,” said Luc Van den hove, CEO at imec. “This is the first time that we have gone this far in the development of our chip technology towards commercialization. With this proof-of-concept, we can demonstrate -much closer to the market- the added value of our technology, while significantly reducing the time-to-market for our partners. The license agreement with miDiagnostics is an important milestone for imec: our breakthrough technology will help curb the COVID-19 pandemic in the foreseeable future.”
imec is already looking further, by investigating how its patented technology can also be applied to diagnose other infectious airborne diseases. In addition, imec is also looking into its application in diagnosing diseases such as cancer.
“Despite the vaccination campaigns, there’s still a great need for accessible and reliable rapid tests to curb new virus outbreaks or to avoid unnecessary quarantine. With our license to imec’s groundbreaking technology, we aim to make our ultra-fast PCR technology, which we now use for nasal swabs, also compatible with exhaled air – the perfect sample for silicon-based PCR. This first prototype will be tested at the airport in November in collaboration with Brussels Airport, Ecolog and Eurofins,” says Katleen Verleysen, CEO of miDiagnostics.
“With the new breathalyzer, we are also making history in testing Covid-19. The development of these tests is of great importance for public health. In this way we will be able to manage this pandemic even better and increase the comfort for people who need to be tested. That is why I am proud that we have been able to support the development and research of imec,” said Flemish Minister of Innovation Hilde Crevits.
- Covid-19 shows a year of medical innovation
- Indoor radar used to fight COVID-19 in smart buildings
- Bosch pushes PCR Covid-19 test time under 30 minutes
- UV-C LED triples radiant flux density for Covid-19 disinfection
- Three team for European smart LED Covid-19 sanitiser
- UK Covid-19 test systems to be built in the Netherlands by US company
Other articles on eeNews Europe
- Stretchable substrate film for soft printed electronics
- Power breakthrough for neuromorphic AI
- Europe to extend investigation of Nvidia-ARM deal
- Intel backs RISC-V for Nios FPGA processor
- Opinion: Politicising semiconductor manufacturing is a global failure
- France in €6bn boost for semiconductors